Fig. 6: Therapeutic efficacy in vivo. | Nature Communications

Fig. 6: Therapeutic efficacy in vivo.

From: DLFea4AMPGen de novo design of antimicrobial peptides by integrating features learned from deep learning models

Fig. 6

a Schematic diagram of the experimental setup for the mice systemic infection model using S. aureus 09057. b–e Bacterial loads of S. aureus 09057 in liver, spleen, lung, and kidney of uninfected mice, and of infected mice after treatment with saline, vancomycin, and D1. f–h Serum levels of TNF-α, IL-1β, and IL-6 in healthy mice and S. aureus-infected mice treated with saline, vancomycin, and D1. i Schematic diagram of the experimental setup for the mice systemic infection model using E. coli z44. j–m Bacterial loads of E. coli z44 in liver, spleen, lung, and kidney of uninfected mice, and of infected mice after treatment with saline, kanamycin, and D1. n–p Serum levels of TNF-α, IL-1β, and IL-6 in healthy mice and E. coli-infected mice treated with saline, kanamycin, and D1. Statistical analysis was conducted using a two-sided one-way ANOVA. Data represent mean ± s.d. of n = 6 biologically independent replicates.

Back to article page